Esmolol vs. Labetalol in Endoscopic Sinus Surgery
| Status: | Completed |
|---|---|
| Conditions: | Sinusitis |
| Therapuetic Areas: | Otolaryngology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/9/2018 |
| Start Date: | March 1, 2017 |
| End Date: | March 30, 2018 |
Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial
The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative
visibility scores in functional endoscopic sinus surgery.
visibility scores in functional endoscopic sinus surgery.
BACKGROUND: Improved intraoperative visibility during functional endoscopic sinus surgery
(FESS) decreases the risk of serious orbital or skull base injuries. Beta blockers are among
several methods used to reduce mean arterial pressure (MAP), heart rate (HR) and mucosal
bleeding. Labetalol (mixed alpha-1-beta blocker) reduces HR and MAP; however, its alpha-1
blockade may mitigate topical epinephrine decongestant effects. Esmolol (selective beta-1
blocker) does not have direct antagonistic effects on topical epinephrine. This study
compares the hemodynamic parameters (rate of blood loss, MAP control, HR) and intraoperative
visibility during FESS between esmolol and labetalol.
(FESS) decreases the risk of serious orbital or skull base injuries. Beta blockers are among
several methods used to reduce mean arterial pressure (MAP), heart rate (HR) and mucosal
bleeding. Labetalol (mixed alpha-1-beta blocker) reduces HR and MAP; however, its alpha-1
blockade may mitigate topical epinephrine decongestant effects. Esmolol (selective beta-1
blocker) does not have direct antagonistic effects on topical epinephrine. This study
compares the hemodynamic parameters (rate of blood loss, MAP control, HR) and intraoperative
visibility during FESS between esmolol and labetalol.
Inclusion Criteria:
- History of CRS with or without nasal polyps
- Undergoing FESS for CRS
- American Society of Anesthesiologists (ASA) physical status 1 (healthy) or 2 (patient
with mild systemic disease).
Exclusion Criteria:
- Pregnancy
- Asthma
- COPD
- Bradycardia
- Heart failure
- End stage renal disease
- Cerebrovascular accident
- Diabetes mellitus
- Preoperative use of NSAIDs, aspirin, or beta-blockers
- Body mass index (BMI) greater than 40 kg/m2.
We found this trial at
1
site
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
